Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5492091/
https://ncbi.nlm.nih.gov/pubmed/28424162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-765685
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados